First Manhattan Co. continued to hold its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,900 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. First Manhattan Co.’s holdings in Jazz Pharmaceuticals PLC were worth $295,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of JAZZ. Somerset Trust Co increased its stake in shares of Jazz Pharmaceuticals PLC by 0.4% in the second quarter. Somerset Trust Co now owns 3,194 shares of the specialty pharmaceutical company’s stock valued at $497,000 after buying an additional 14 shares during the period. Level Four Advisory Services LLC increased its stake in Jazz Pharmaceuticals PLC by 0.8% in the first quarter. Level Four Advisory Services LLC now owns 2,729 shares of the specialty pharmaceutical company’s stock worth $389,000 after buying an additional 23 shares during the last quarter. World Asset Management Inc increased its stake in Jazz Pharmaceuticals PLC by 1.9% in the second quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock worth $224,000 after buying an additional 27 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its stake in Jazz Pharmaceuticals PLC by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock worth $217,000 after buying an additional 44 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. increased its stake in Jazz Pharmaceuticals PLC by 0.8% in the first quarter. Nomura Asset Management Co. Ltd. now owns 6,550 shares of the specialty pharmaceutical company’s stock worth $951,000 after buying an additional 50 shares during the last quarter. 86.43% of the stock is currently owned by institutional investors.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 142.90 on Thursday. The company’s 50 day moving average price is $155.68 and its 200-day moving average price is $146.56. The stock has a market capitalization of $8.58 billion, a PE ratio of 21.59 and a beta of 1.10. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.85 by $0.13. The company had revenue of $394.39 million during the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 23.80%. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter last year, the business posted $2.67 earnings per share. Equities research analysts predict that Jazz Pharmaceuticals PLC will post $11.02 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/first-manhattan-co-maintains-position-in-jazz-pharmaceuticals-plc-jazz/1468679.html.

JAZZ has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Thursday, April 27th. Leerink Swann set a $179.00 price objective on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Thursday, April 27th. Zacks Investment Research downgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. Cowen and Company reaffirmed an “outperform” rating and issued a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, May 10th. Finally, Royal Bank Of Canada initiated coverage on Jazz Pharmaceuticals PLC in a research note on Monday, May 15th. They issued an “outperform” rating and a $210.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $182.96.

In related news, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock in a transaction on Monday, July 17th. The stock was sold at an average price of $154.97, for a total value of $30,994.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Suzanne Sawochka Hooper sold 420 shares of Jazz Pharmaceuticals PLC stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $160.00, for a total value of $67,200.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,600 shares of company stock valued at $1,641,720. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.